Vorapaxar

Drug Profile

Vorapaxar

Alternative Names: MK-5348; SCH 530348; TRA; TRA-SCH 530348; Vorapaxar sulfate; Zontivity

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Duke Clinical Research Institute; Kirby Institute for infection and immunity in society; Merck & Co
  • Class 3-ring heterocyclic compounds; Antithrombotics; Carbamates; Cardiovascular therapies; Lactones; Pyridines
  • Mechanism of Action PAR 1 receptor antagonists; Thrombin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial thrombosis
  • Phase I/II Blood coagulation disorders; Inflammation
  • No development reported Cerebral infarction

Most Recent Events

  • 24 Apr 2017 Aralez Pharmaceuticals re-launches vorapaxar in USA
  • 13 Mar 2017 Aralez plans to re-launch vorapaxar in USA in June 2017
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top